Nexstim Plc · OMXHEX:NXTMH
Nexstim — BioTrinity 2018
17 slides from Nexstim's conference presentation, Apr 24, 2018
Slide 1: World leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson| CEO & Chairman of the Board | Nexstim Plc Mikko Karvinen| CFO | Nexstim Plc Corporate Presentation, BioTrinity, London 24 April 2018 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj Certain of the information contained herein concerning industry and market data, economic (“Nexstim” or the “Company”). In connection with any presentation or review of this trends, market pos
Slide 3: Nexstim Plc at a Glance
Nexstim Plc at a Glance ● We have a pioneering electric (e) field navigated neuro stimulation technology (eTMS) ● Listed in Nasdaq First North Finland & Sweden with about 6000 shareholders ● 93m+ outstanding shares, SITRA largest shareholder ● Independent Board of Directors ● Established sales in US
Slide 4: E-Field Navigation Differentiates Nexstim TMS
E-Field Navigation Differentiates Nexstim TMS ● Unique e-field induced modeling ● Highly accurate targeting ● Precise dosing ● Repeatable over multiple treatment sessions ● Fully integrated system ensures quality and accuracy ● TMS ● Proprietary e-field modeling that enables accurate stimulation tar
Slide 5: Our Technology – Applications
Our Technology – Applications Technology Applications – current focus Therapy Stroke Depression Chronic pain Navigated Brain Therapy (NBT) Europe US Europe US Europe US CE marked Phase III CE marked FDA CE marked Multi- trial cleared centre underway clinicals planned Diagnostic Pre-surgical mapping
Slide 6: NBS Pre-Surgical Mapping significantly improves clinical outcomes
NBS Pre-Surgical Mapping significantly improves clinical outcomes • NBS demonstrates the value of our unique navigation system • Allows the surgeon to be better prepared and more aggressive with the tumour resection Progression-free Survival (Months) Direct Cortical Stimulation 46% Increase in PFS i
Slide 7: World Leading Centers Rely on NBS Pre-Surgical Mapping
World Leading Centers Rely on NBS Pre-Surgical Mapping 7
Slide 8: Navigated Brain Therapy: Reproducible specifically targeted transcranial stimulation
Navigated Brain Therapy® Reproducible specifically targeted transcranial stimulation @NexstimOyj
Slide 9: NBT has potential for multiple therapeutic applications due to precise navigation
NBT® (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation Stroke Rehabilitation Therapy • E-FIT supplementary Phase III trial Depression Therapy underway • CE marked • CE marked • FDA cleared Chronic Pain Therapy • CE marked Primary focus is Stroke,
Slide 10: NBT for depression
NBT® for depression ● Major depressive disorder affects >300 million people worldwide ● Existing psychotherapy and pharmacological treatment options are suboptimal ● Without navigation, the exact cortex area - Dorso Lateral Pre Frontal Cortex - requiring TMS treatment is correctly targeted in just 3
Slide 11: Market opportunity in stroke rehabilitation
Market opportunity in stroke rehabilitation 2015 Incidence of stroke 2015 Stroke survivors USA USA 0.8 M 6.5 M China China 15 M Europe 2.5 M (7.5 M)* Europe 1.2 M 8.0 M *Published data • Large and rapidly growing market • 50% of stroke survivors will have upper limb paralysis with few available trea
Slide 12: Supplementary E-FIT Trial to Support FDA Clearance
Supplementary E-FIT Trial to Support FDA Clearance Supplementary E-FIT trial ● 60 patients – 5 leading US centers ● Similar results expected in the active patient group as per the NICHE study which showed a clinically meaningful response in 2/3 of patients NBT® ● Active group data from Phase III (NI
Slide 13: NBT for chronic pain
NBT® for chronic pain ● 40-50% of neuropathic pain patients are without effective pain relief ● Study conducted by The Walton Centre, UK stated that 44% of patients undergoing NBT therapy reported clinically meaningful pain relief of at least 3 weeks' duration ● The Walton Centre is currently conduc
Slide 14: Nexstim Milestones
Nexstim Milestones ● US launch for depression – Q2 2018 ● Complete E-FIT multi-center trial – mid 2018 ● File stroke 510k Denovo – H2 2018 ● Stroke commercial launch – H1 2019 14
Slide 15: Nexstim Financing Round to Support Strategic Initiatives
Nexstim Financing Round to Support Strategic Iniatives ● Timing: H2 2018 ● Structure: To be finalized ● Objectives: 1. Support the US commercial launch of our stroke rehabilitation application 2. Complete our therapy clinical trial programme 15
Slide 16: Nexstim Milestones - Clinical trial plan
Nexstim Milestones - Clinical trial plan 2018 2019 2020 2021 2022 2023 All indications Registry for depression, stroke and chronic pain data collection Stroke E-FIT Trials to replicate E-FIT for reimbursement (5, US) 2019-2021 Multi-center trial in chronic stroke 2019-2021 Multi-center trial in suba
Slide 17: Thank you
Thank you @NexstimOyj